HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · IEX Real-Time Price · USD
1.100
0.00 (0.00%)
At close: May 17, 2024, 4:00 PM
1.010
-0.090 (-8.18%)
After-hours: May 17, 2024, 7:30 PM EDT

Company Description

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States.

The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.

It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment.

The company was incorporated in 2018 and is headquartered in Miramar, Florida.

HCW Biologics Inc.
HCW Biologics logo
Country United States
Founded 2018
IPO Date Jul 20, 2021
Industry Biotechnology
Sector Healthcare
Employees 45
CEO Dr. Hing C. Wong Ph.D.

Contact Details

Address:
2929 N Commerce Pkwy
Miramar, Florida 33025
United States
Phone 954-842-2024
Website hcwbiologics.com

Stock Details

Ticker Symbol HCWB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $8.00
CIK Code 0001828673
CUSIP Number 40423R105
ISIN Number US40423R1059
Employer ID 82-5024477
SIC Code 2834

Key Executives

Name Position
Dr. Hing C. Wong Ph.D. Founder, Chief Executive Officer, Director and Secretary
Rebecca Byam CPA, M.B.A. Chief Financial Officer
Dr. Peter Rhode Ph.D. Chief Scientific Officer and Vice President of Clinical Operations
Nicole Valdivieso Esq. Vice President of Legal Affairs
Raquel Diaz M.S. Director of Human Resources
Lee D. Flowers Senior Vice President of Business Development

Latest SEC Filings

Date Type Title
May 15, 2024 10-Q Quarterly Report
May 15, 2024 8-K Current Report
May 15, 2024 10-K/A [Amend] Annual report
May 3, 2024 8-K Current Report
May 1, 2024 8-K Current Report
Apr 26, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 26, 2024 ARS Filing
Apr 26, 2024 DEF 14A Other definitive proxy statements
Apr 1, 2024 10-K Annual Report
Apr 1, 2024 8-K Current Report